BR112021021838A8 - Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina - Google Patents
Método para tratar dor associada à endometriose com uso de composto de diaminopirimidinaInfo
- Publication number
- BR112021021838A8 BR112021021838A8 BR112021021838A BR112021021838A BR112021021838A8 BR 112021021838 A8 BR112021021838 A8 BR 112021021838A8 BR 112021021838 A BR112021021838 A BR 112021021838A BR 112021021838 A BR112021021838 A BR 112021021838A BR 112021021838 A8 BR112021021838 A8 BR 112021021838A8
- Authority
- BR
- Brazil
- Prior art keywords
- endometriosis
- pain associated
- treatment
- compound
- diaminopyrimidine
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 3
- -1 DIAMINOPYRIMIDINE COMPOUND Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019085209 | 2019-04-30 | ||
| PCT/CN2020/087689 WO2020221277A1 (zh) | 2019-04-30 | 2020-04-29 | 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021021838A2 BR112021021838A2 (pt) | 2022-01-04 |
| BR112021021838A8 true BR112021021838A8 (pt) | 2023-02-28 |
Family
ID=73028778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021838A BR112021021838A8 (pt) | 2019-04-30 | 2020-04-29 | Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12605381B2 (https=) |
| EP (1) | EP3960178B1 (https=) |
| JP (1) | JP7663508B2 (https=) |
| KR (1) | KR102935431B1 (https=) |
| CN (1) | CN114007620B (https=) |
| AU (1) | AU2020266947B2 (https=) |
| BR (1) | BR112021021838A8 (https=) |
| CA (1) | CA3138238A1 (https=) |
| MX (1) | MX2021013347A (https=) |
| SG (1) | SG11202111960PA (https=) |
| TW (1) | TWI737285B (https=) |
| WO (1) | WO2020221277A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7207634B2 (ja) | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
| US20250032476A1 (en) * | 2021-11-05 | 2025-01-30 | The Regents Of The University Of California | Alpha-2a adrenergic receptor modulators and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| MA43821A (fr) * | 2016-03-14 | 2018-11-28 | Afferent Pharmaceuticals Inc | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| MA44489A (fr) | 2016-03-25 | 2019-01-30 | Afferent Pharmaceuticals Inc | Pyrimidines et variants de celles-ci, et leurs utilisations |
| JP7207634B2 (ja) * | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
| USD956213S1 (en) | 2020-10-02 | 2022-06-28 | Phillips-Medisize A/S | Autoinjector |
-
2020
- 2020-04-29 SG SG11202111960PA patent/SG11202111960PA/en unknown
- 2020-04-29 US US17/607,475 patent/US12605381B2/en active Active
- 2020-04-29 CA CA3138238A patent/CA3138238A1/en active Pending
- 2020-04-29 KR KR1020217038622A patent/KR102935431B1/ko active Active
- 2020-04-29 EP EP20798599.5A patent/EP3960178B1/en active Active
- 2020-04-29 JP JP2021564186A patent/JP7663508B2/ja active Active
- 2020-04-29 WO PCT/CN2020/087689 patent/WO2020221277A1/zh not_active Ceased
- 2020-04-29 BR BR112021021838A patent/BR112021021838A8/pt unknown
- 2020-04-29 AU AU2020266947A patent/AU2020266947B2/en active Active
- 2020-04-29 MX MX2021013347A patent/MX2021013347A/es unknown
- 2020-04-29 CN CN202080032509.8A patent/CN114007620B/zh active Active
- 2020-04-30 TW TW109114698A patent/TWI737285B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7663508B2 (ja) | 2025-04-16 |
| BR112021021838A2 (pt) | 2022-01-04 |
| KR20220008286A (ko) | 2022-01-20 |
| CN114007620B (zh) | 2024-08-06 |
| SG11202111960PA (en) | 2021-12-30 |
| CA3138238A1 (en) | 2020-11-05 |
| EP3960178A1 (en) | 2022-03-02 |
| JP2022531570A (ja) | 2022-07-07 |
| US20220249478A1 (en) | 2022-08-11 |
| MX2021013347A (es) | 2022-01-24 |
| TW202106303A (zh) | 2021-02-16 |
| KR102935431B1 (ko) | 2026-03-05 |
| CN114007620A (zh) | 2022-02-01 |
| WO2020221277A1 (zh) | 2020-11-05 |
| EP3960178B1 (en) | 2026-03-18 |
| US12605381B2 (en) | 2026-04-21 |
| TWI737285B (zh) | 2021-08-21 |
| AU2020266947A1 (en) | 2021-12-16 |
| EP3960178A4 (en) | 2023-01-25 |
| AU2020266947B2 (en) | 2025-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017354A2 (pt) | Método para o tratamento de doença hepática adiposa e/ou esteatoepatite | |
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| BR112021026214A2 (pt) | Método para tratamento de fibrose pulmonar idiopática | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR112022000231A2 (pt) | Novos métodos | |
| BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
| BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| BR112022009209A2 (pt) | Derivado de amida e método de preparação e uso do mesmo na medicina | |
| BR112015009037A2 (pt) | composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 | |
| BR112017016087A2 (pt) | formulações para coxim articular adiposo e métodos de uso das mesmas | |
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| BR112017016428A2 (pt) | ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório? | |
| BR112021021838A8 (pt) | Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina | |
| PH12022550441A1 (en) | Azaheteroaryl compound and application thereof | |
| BRPI0807940B8 (pt) | usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido | |
| BR112022008677A2 (pt) | Terapia de combinação com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidina-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| BR112012020060B8 (pt) | uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência | |
| BR112015012497A2 (pt) | combinações farmacêuticas |